Clinical trials: Overweight, Obesity
Diabetes Mellitus Type 2
Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects
This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.
- Trial name
- NCT01807377
- Testing
- PF-05175157, Midazolam
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)
The purpose of this study is to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day cycles of escalating oral doses of MP 101 in 100 obese adult subjects.
- Trial name
- NCT00449202
- Testing
- oleoyl-estrone (MP 101)
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 100 people
- Sponsor
- Manhattan Pharmaceuticals
Obesity
Methods Study to Characterize Early Indicators of Weight Loss in People
Methods study to characterize early indicators of weight loss in people.
- Trial name
- NCT00383253
- Testing
- caloric restriction - 10%, caloric restriction - 25%, caloric restriction - 50%
- Where
- 2 sites in Australia
- Volunteers
- 57 people
- Sponsor
- Pfizer
Overweight and Obesity
Clinical Study Protocol for the Assessment of Safety and Efficacy of the BARICLIP®
Overweight and obesity are at epidemic proportions in the world population as well as in the United States, where nearly 42% of the adult population(1) is considered to meet the definition of obesity, namely a body mass index…
- Trial name
- NCT06338709
- Testing
- BariClip® Device Treatment
- Volunteers
- 165 people
- Sponsor
- Advanced Bariatric Technology
Obesity, Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study.
- Trial name
- NCT05649137
- Testing
- Semaglutide
- Where
- 76 sites in United States, Bulgaria and 6 more
- Volunteers
- 512 people
- Sponsor
- Novo Nordisk A/S
Overweight
Influence of a Food Supplement on the Gut Microbiome in Healthy Obese Women
Before and after study in obese women 25-35 years old, BMI 30-35, taking Strath® Kräuterhefe Original (liquid), Herbal Yeast Food Supplement for three weeks.
- Trial name
- NCT03223987
- Testing
- Strath® Kräuterhefe Original (liquid)
- Where
- Switzerland
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bio-Strath AG
Obesity, Overweight
Current Status of Cardiovascular Diseases in Chinese Overweight/ Obesity Population: An Epidemiological Study (COPE）
This study is testing how overweight and obesity affect cardiovascular disease (CVD) prevalence, risk factors, and mortality among Chinese adults using nationally representative CCDRFS (China Chronic Disease and Risk Factor…
- Trial name
- COPE (NCT07358052)
- Testing
- No treatment given
- Where
- 2 sites in China
- Volunteers
- 551,931 people
- Sponsor
- Novo Nordisk A/S
Obesity
Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight.
- Trial name
- OUTSTEP-1 (NCT07154238)
- Testing
- No treatment given
- Where
- Germany
- Volunteers
- 2,546 people
- Sponsor
- Novo Nordisk A/S
Chronic Management of Body Weight
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
- Trial name
- NCT07670884
- Testing
- HRS9531 Tablet
- Where
- 2 sites in China
- Volunteers
- 675 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2, Obesity
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes.
- Trial name
- NCT05514535
- Testing
- Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated)
- Where
- 239 sites in United States, Czechia and 10 more
- Volunteers
- 573 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Obesity
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
To determine if the EndoBarrier safely and effectively improves glycemic control in obese subjects with type 2 diabetes
- Trial name
- ENDO (NCT01728116)
- Testing
- EndoBarrier
- Where
- 25 sites in United States
- Volunteers
- 325 people
- Sponsor
- Morphic Medical Inc.
Obesity (BMI>30), Obesity & Overweight
Allurion Gastric Balloon PAS
The primary purpose of this study is to confirm the safety profile results for the Allurion Gastric Balloon System (AGBS).
- Trial name
- NCT07684664
- Testing
- Active Elipse Device
- Volunteers
- 250 people
- Sponsor
- Allurion Technologies
Healthy, Fatty Liver
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
A generic screening study to establish structural and/or functional baselines of specific organs.
- Conditions
- Healthy, Fatty Liver, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- MASLD (NCT04873258)
- Testing
- Bioimpedence Vector Analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
Obesity / Overweight, Obesity (BMI Equal to or >30)
A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.
This study is designed as a single-blind, placebo-controlled, randomized, parallel-group trial. Subjects will be randomized in a 2:1 ratio to receive either NKS-3 or matching placebo, with a total planned enrollment of 31…
- Trial name
- SERENITY-1 (NCT07882654)
- Testing
- Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120
- Where
- Tunisia
- Volunteers
- 31 people
- Sponsor
- EktaH
Overweight, Obesity
A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
The study will look at how two different forms of semaglutide reach and stay in the blood after injection. None of the two forms of semaglutide have been approved by the authorities to treat obesity, but it has been approved as a…
- Trial name
- NCT04187300
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Novo Nordisk A/S
Sleep Apnea, Obstructive, Obesity Hypoventilation Syndrome
Feasibility of a Modified Positive Airway Pressure Device to Treat Sleep Disordered Breathing
This study will use a modified version of a positive airway pressure device to supply air to the participant, while undergoing supervised polysomnography.
- Trial name
- NCT02368639
- Testing
- Fisher & Paykel Healthcare PAP Device
- Where
- New Zealand
- Volunteers
- 14 people
- Sponsor
- Fisher and Paykel Healthcare
Metabolic Syndrome, Obesity Hypoventilation Syndrome
Obesity-hypoventilation in Metabolic Syndrom Patients
The purpose of the study is to determined the prevalence of obesity-hypoventilation syndrome in patients with metabolic syndrom.
- Conditions
- Metabolic Syndrome, Obesity Hypoventilation Syndrome, Capnography
- Trial name
- NCT04839419
- Where
- France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- SOS Oxygene Mediterranee
Overweight, Obesity
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.
The study is testing a new medicine (NNC0487-0111) for weight control in Chinese people with BMI between 24 kilogram per meter square (kg/m2) and 34.9 kg/m2.
- Trial name
- NCT07121153
- Testing
- NNC0487-0111 A
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Type II Diabetes Mellitus, Obesity
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
One out of two adults in Canada is currently overweight and therefore at increased risk for a number of medical conditions including diabetes, high blood pressure, heart attacks and stroke.
- Trial name
- NCT01644201
- Testing
- PolyGlycopleX® - PGX®
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- InovoBiologic Inc.
Diabetes Mellitus, Type 2, Obesity
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body.
- Trial name
- NCT00494767
- Testing
- GW869682, GSK189075
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.